Drug Trial Radar · NCT01032629
CANVAS - CANagliflozin cardioVascular Assessment Study
Last checked: Nov 19, 2026Latest source record: Dec 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,330
Actual
Start
Dec 9, 2009
Primary completion
Feb 22, 2017
Study completion Feb 22, 2017
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- The George Institute for Global Health, Australia
- First posted
- Dec 15, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE). Other objectives include evaluating the overall safety, tolerability, and effectiveness of canagliflozin. The data from this study will be combined with the data from CANVAS-R study (Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM, NCT01989754) in a pre-specified integrated analysis of CV safety outcomes to satisfy US FDA post-marketing requirements for canagliflozin.
Conditions
- Diabetes Mellitus, Type 2
- Cardiovascular Diseases
- Risk Factors
Interventions
PlaceboDrug
One placebo capsule taken orally (by mouth) once daily
Canagliflozin (JNJ-28431754) 100 mgDrug
One 100 mg capsule taken orally (by mouth) once daily
Canagliflozin (JNJ-28431754) 300 mgDrug
One 300 mg capsule taken orally (by mouth) once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal StrokeTime frame: Up to approximately 8 years
Locations
305 sites in 25 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mesa, Arizona
Site not named
Tucson, Arizona
Site not named
La Mesa, California
Site not named
Los Gatos, California
Site not named
Pismo Beach, California
Site not named
Stockton, California
Site not named
Walnut Creek, California
Site not named
Doral, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Plantation, Florida
Site not named
Atlanta, Georgia
Site not named
Duluth, Georgia
Site not named
Boise, Idaho
Site not named
Eagle, Idaho
Site not named
Meridian, Idaho
Site not named
Peoria, Illinois
Site not named
Topeka, Kansas
Site not named
Crestview Hills, Kentucky
Site not named
Lexington, Kentucky
Site not named
Auburn, Maine
Site not named
Scarborough, Maine
Site not named
Oxon Hill, Maryland
Site not named
Royal Oak, Michigan
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Camden, New Jersey
Site not named
Flushing, New York
Site not named
The Bronx, New York
Site not named
Chapel Hill, North Carolina
Site not named
Charlotte, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Site not named
Gallipolis, Ohio
Site not named
Mentor, Ohio
Site not named
Toledo, Ohio
Showing 40 of 305 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.